01:44 , Aug 16, 2019 |  BC Innovations  |  Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
21:54 , Apr 22, 2019 |  BC Extra  |  Company News

Variant expands pipeline with InflamaCore inflammasome deal

InflamaCore granted Variant exclusive, worldwide rights to develop and commercialize IC 100 and related products to treat inflammatory diseases. Variant Pharmaceuticals Inc. (Weston, Fla.) also gained rights to develop companion diagnostics for the mAb targeting...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
16:59 , Jul 27, 2018 |  BC Week In Review  |  Company News

CMS to overhaul Part B drug purchasing

CMS is moving forward with plans to overhaul the way Medicare purchases infused and injected drugs that are administered under a physician’s supervision. It has requested public comment on proposals for implementing a Competitive Acquisition...
21:20 , Jul 26, 2018 |  BC Extra  |  Politics & Policy

CMS to overhaul Part B drug purchasing

CMS is moving forward with plans to overhaul the way Medicare purchases infused and injected drugs that are administered under a physician’s supervision. It has requested public comment on proposals for implementing a Competitive Acquisition...
17:38 , Jul 20, 2018 |  BC Week In Review  |  Financial News

IFM launches subsidiary with $31M series A

IFM Therapeutics LLC (Boston, Mass.) launched inflammatory disease-focused subsidiary IFM Tre Inc. with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management. IFM Tre will develop...
20:38 , Jul 19, 2018 |  BC Extra  |  Financial News

IFM launches subsidiary with $31M series A

IFM Therapeutics LLC (Boston, Mass.) launched inflammatory disease-focused subsidiary IFM Tre Inc. with a $31 million series A round co-led by Atlas Venture, Abingworth, Bristol-Myers Squibb Co. (NYSE:BMY) and IFM’s management. IFM Tre will develop...
03:19 , Jan 19, 2018 |  BC Innovations  |  Strategy

After amyloid

As the Alzheimer’s field is slowly taking on the search for new targets outside of the β amyloid and tau hypotheses, researchers are ramping up exploration of new pathways and looking to the disease’s genetics...
19:23 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample and mouse studies suggest inhibiting PYCARD or its downstream effector IL-18 could help treat gastric cancer. In tumor samples from patients, levels of PYCARD and IL-18 were higher than in...
01:15 , Jan 12, 2018 |  BC Innovations  |  Product R&D

Avidity’s affinity for muscle

Avidity Biosciences LLC has developed a strategy for delivering siRNA and antisense therapies to tissues outside the liver and has preclinical proof-of-concept for two molecules that target muscle. The company has set its next sights...